ABSTRACT
Introduction Consumer wearable devices with health and wellness features are increasingly common and may enhance prevention and management of cardiovascular disease. However, the characteristics and attitudes of wearable device users versus non-users are poorly understood.
Methods Wearable Activity Tracking for Comprehensive Healthcare-Integrated Technology (WATCH-IT) was a prospective study of adults aged ≥18 years receiving longitudinal primary or ambulatory cardiovascular care at one of eleven hospitals within the Mass General Brigham multi-institutional healthcare system between January 2010-July 2021. We invited patients, including wearable users and non-users, to participate via an electronic patient portal. Participants were asked to complete a 20-question survey regarding perceptions and use of consumer wearable devices. Responses were linked to electronic health record data. Multivariable logistic regression was used to identify factors associated with device use.
Results Among 280,834 individuals receiving longitudinal primary or cardiovascular care, 65,842 did not have an active electronic portal or opted out of research contact. Of the 214,992 individuals sent a survey link, 11,121 responded (5.2%), comprising the WATCH-IT patient sample. Most respondents (55.8%) reported current use of a wearable device, and most non-users (95.3%) reported they would use a wearable device if provided at no cost. Although most users (70.2%) had not shared device data with their doctor previously, the majority believed it would be very (20.4%) or moderately (34.4%) important to share device-related health information with providers. In multivariable models, older age (odds ratio [OR] 0.80 per 10-year increase, 95% CI 0.77-0.82), male sex (0.87, 95% CI 0.80-0.95), and heart failure (0.75, 95% CI 0.63-0.89) were associated with lower odds of wearable device use, whereas higher median zip code income (1.08 per 1-quartile increase, 95% CI 1.04-1.12) and care in a cardiovascular medicine clinic (1.17, 95% CI 1.05-1.30) were associated with greater odds of device use. Nearly all respondents (98%) stated they would share device data with researchers studying health outcomes.
Conclusions Within an electronically assembled cohort of patients in primary and cardiovascular medicine clinics with linkage to detailed health records, wearable device use is common. Most users perceive value in wearable data. Our platform may enable future study of the relationships between wearable technology and resource utilization, clinical outcomes, and health disparities.
Competing Interest Statement
Dr. Ellinor receives sponsored research support from Bayer AG and IBM Research; he has also served on advisory boards or consulted for Bayer AG, MyoKardia and Novartis. Dr. Atlas receives sponsored research support from Bristol Myers Squibb-Pfizer and Fitbit. He receives sponsored research funding from Bristol Myers Squibb-Pfizer and has consulted for Boehringer Ingelheim, Bristol Myers Squibb-Pfizer, Fitbit, Johnson & Johnson, and Merck. Dr. Lubitz is an employee of Novartis Institutes for Biomedical Research as of July 2022. Dr. Lubitz previously received sponsored research support from Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, Fitbit, Medtronic, Premier, and IBM, and has consulted for Bristol Myers Squibb, Pfizer, Blackstone Life Sciences, and Invitae. Dr. McManus has received research support from Bristol Myers Squibb-Pfizer, Boehringer Ingelheim and Fitbit, and has received consulting fees from Fitbit, Heart Rhythm Society, Avania, Venturewell, and NAMSA. Dr. Singer receives research support from Bristol Myers Squibb-Pfizer and has received consulting fees from Bristol Myers Squibb, Pfizer, Fitbit, Medtronic, and Google.
Clinical Trial
N/A
Funding Statement
Dr. Al-Alusi is supported by a grant from the National Institutes of Health (T32-HL007208). Dr. Ellinor is supported by grants from the National Institutes of Health (1R01HL092577, 1R01HL157635, 1R01HL157635), by a grant from the American Heart Association Strategically Focused Research Networks (18SFRN34110082), and by a grant from the European Union (MAESTRIA 965286). Dr. McManus is supported by grants from the National Institutes of Health (U54HL143541, R01HL141434, R33HL158541, and R01HL155343). Dr. Singer is supported, in part, by the Eliot B. and Edith C. Shoolman Fund of Massachusetts General Hospital. Dr. Lubitz previously received support from NIH grants R01HL139731 and R01HL157635, and American Heart Association 18SFRN34250007 during this project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Survey respondents provided informed consent and all study protocols were approved by the MGB Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Raw identifiable data included in this manuscript are not available due to privacy considerations.
